Literature DB >> 23152559

Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.

Eva Schlecker1, Ana Stojanovic, Christian Eisen, Christian Quack, Christine S Falk, Viktor Umansky, Adelheid Cerwenka.   

Abstract

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells in cancer patients and tumor-bearing mice that potently inhibits T cell responses. During tumor progression, MDSCs accumulate in several organs, including the tumor tissue. So far, tumor-infiltrating MDSC subpopulations remain poorly explored. In this study, we performed global gene expression profiling of mouse tumor-infiltrating granulocytic and monocytic (MO-MDSC) subsets compared with MDSCs from peripheral blood. RMA-S lymphoma-infiltrating MO-MDSCs not only produced high levels of NO and arginase-1, but also greatly increased levels of chemokines comprising the CCR5 ligands CCL3, CCL4, and CCL5. MO-MDSCs isolated from B16 melanoma and from skin tumor-bearing ret transgenic mice also expressed high levels of CCL3, CCL4, and CCL5. Expression of CCR5 was preferentially detected on regulatory T cells (Tregs). Accordingly, tumor-infiltrating MO-MDSCs directly attracted high numbers of Tregs via CCR5 in vitro. Intratumoral injection of CCL4 or CCL5 increased tumor-infiltrating Tregs, and deficiency of CCR5 led to their profound decrease. Moreover, in CCR5-deficient mice, RMA-S and B16 tumor growth was delayed emphasizing the importance of CCR5 in the control of antitumor immune responses. Overall, our data demonstrate that chemokines secreted by tumor-infiltrating MO-MDSCs recruit high numbers of Tregs revealing a novel suppressive role of MDSCs with potential clinical implications for the development of cancer immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152559     DOI: 10.4049/jimmunol.1201018

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  176 in total

1.  Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Authors:  J Yan; C Tingey; R Lyde; T C Gorham; D K Choo; A Muthumani; D Myles; L P Weiner; K A Kraynyak; E L Reuschel; T H Finkel; J J Kim; N Y Sardesai; K E Ugen; K Muthumani; D B Weiner
Journal:  Cancer Gene Ther       Date:  2014-11-14       Impact factor: 5.987

Review 2.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

3.  Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.

Authors:  Xiaowei Chen; Yoshihiro Takemoto; Huan Deng; Moritz Middelhoff; Richard A Friedman; Timothy H Chu; Michael J Churchill; Yan Ma; Karan K Nagar; Yagnesh H Tailor; Siddhartha Mukherjee; Timothy C Wang
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

4.  Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses.

Authors:  N Rieber; C Gille; N Köstlin; I Schäfer; B Spring; M Ost; H Spieles; H A Kugel; M Pfeiffer; V Heininger; M Alkhaled; A Hector; L Mays; M Kormann; S Zundel; J Fuchs; R Handgretinger; C F Poets; D Hartl
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

Review 5.  Roles of regulatory T cells in cancer immunity.

Authors:  Yoshiko Takeuchi; Hiroyoshi Nishikawa
Journal:  Int Immunol       Date:  2016-05-09       Impact factor: 4.823

6.  CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.

Authors:  Qiu Tang; Jun Jiang; Jian Liu
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 7.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

8.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Authors:  Veronika Bachanova; Dhifaf Sarhan; Todd E DeFor; Sarah Cooley; Angela Panoskaltsis-Mortari; Bruce R Blazar; Julie M Curtsinger; Linda Burns; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2017-12-07       Impact factor: 6.968

Review 9.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

10.  PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Authors:  Jianfeng Shen; Wei Zhao; Zhenlin Ju; Lulu Wang; Yang Peng; Marilyne Labrie; Timothy A Yap; Gordon B Mills; Guang Peng
Journal:  Cancer Res       Date:  2018-11-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.